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Abstract
The prevalence of heteroresistant Acinetobacter baumannii is increasing. Infections due to these 
resistant pathogens pose a global treatment challenge. Here, the pharmacodynamic activities of 
polymyxin B (PMB) (2–20 mg/L) and tigecycline (0.15–4 mg/L) were evaluated as monotherapy 
and in combination using a 4 × 4 concentration array against two carbapenem-resistant and 
polymyxin-heteroresistant A. baumannii isolates. Time Kill Experiments was employed at starting 
inocula of 106 and 108 CFU/mL over 48 h. Clinically relevant combinations of PMB (2 mg/L) and 
tigecycline (0.90 mg/L) resulted in greater reductions in the bacterial population compared with 
polymyxin alone by 8 h (ATCC 19606, −6.38 vs. −3.43 log10 CFU/mL; FADDI AB115, −1.38 vs. 
2.08 log10 CFU/mL). At 10× the clinically achievable concentration (PMB 20 mg/L in 
combination with tigecycline 0.90 mg/L), there was bactericidal activity against FADDI AB115 by 
4 h that was sustained until 32 h, and against ATCC 19606 that was sustained for 48 h. These 
studies show that aggressive polymyxin-based dosing in combination with clinically achievable 
tigecycline concentrations results in early synergistic activity that is not sustained beyond 8 h, 
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whereas combinations with higher tigecycline concentrations result in sustained bactericidal 
activity against both isolates at both inocula. These results indicate a need for optimised front-
loaded polymyxin-based combination regimens that utilise high polymyxin doses at the onset of 
treatment to achieve good pharmacodynamic activity whilst minimising adverse events.
Keywords
Polymyxins; Polymyxin B; Tigecycline; Pharmacodynamics; Combinations; Acinetobacter 
baumannii
1. Introduction
The intrinsic impermeability of the outer membrane of Acinetobacter baumannii has allowed 
it to acquire highly effective resistance determinants, making it a reservoir of resistance 
genes. The emergence of multidrug-resistant (MDR) A. baumannii strains resistant to nearly 
all commercially available antibiotics has compromised treatment options against these 
pathogens. Owing to their nephrotoxicity, old antibiotics such as polymyxins have been 
abandoned in favour of newer agents such as tigecycline. However, both of these antibiotics 
are attracting attention as two of the remaining effective antibiotics against MDR A. 
baumannii.
Polymyxin B (PMB) is a polypeptide polymyxin that has not undergone the rigour of 
modern drug development but is increasingly being utilised as a drug of last resort. In 
contrast, tigecycline is a newer broad-spectrum glycylcycline antibiotic that can evade 
tetracycline efflux pumps (TetA–E) in MDR A. baumannii [1]. The emergence of polymyxin 
heteroresistance has been reported among A. baumannii strains and is associated with 
clinical failure. Amplification of existing resistant subpopulations among heteroresistant A. 
baumannii in response to polymyxin monotherapy may be the main driver responsible for 
promoting resistance, especially when there is high bacterial density. The substantial 
increase in resistant subpopulations observed upon exposure to polymyxin suggests that 
sufficiently high drug pressure is required at the start of therapy to eradicate these resistant 
subpopulations. However, PMB monotherapy is not usually a clinical option, since dose 
escalation to achieve sufficiently high concentrations with currently recommended dosing 
protocols risks rapid-onset nephrotoxicity [2]. Furthermore, tigecycline is not recommended 
for severe difficult-to-treat MDR A. baumannii infections, despite their susceptibility to 
tigecycline, owing to the reported clinical failures, poor outcomes and disappointing 
bacteriostatic activity [3].
Consequently, clinicians faced with limited treatment options are resorting to combination 
therapy to treat patients infected with MDR A. baumannii. Optimisation and validation of 
polymyxin-based combinations would therefore be of considerable clinical benefit. The 
pharmacodynamics of combination antimicrobial therapy with PMB and tigecycline is 
poorly defined, especially in situations of high bacterial density and pre-existing polymyxin 
heteroresistance. The objective of the current study was to systemically investigate the in 
vitro pharmacodynamics of PMB and tigecycline at clinically achievable and higher 
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concentrations against polymyxin-heteroresistant A. baumannii isolates and to quantify their 
activity profiles for possible clinical translation.
2. Materials and methods
Two carbapenem-resistant and polymyxin-heteroresistant A. baumannii isolates were used: a 
PMB-susceptible (PBS) reference strain ATCC 19606 [minimum inhibitory concentrations 
(MICs): PMB, 0.5 mg/L; tigecycline, 2.0 mg/L; and meropenem, 16 mg/L] and a PMB-
resistant (PBR) clinical isolate FADDI AB115 (MICs: PMB, >8.0 mg/L; tigecycline, 2.0 
mg/L; and meropenem 16 mg/L). The MICs for tigecycline and PMB were determined in 
quadruplicate by broth dilution [4]. Colistin heteroresistance was defined as the presence of 
bacterial subpopulations able to grow on agar containing >2.0 mg/L colistin when the MIC 
was ≤2.0 mg/L [5]. PMB (Sigma-Aldrich, St Louis, MO) and tigecycline (Pfizer Inc., New 
York, NY) were dissolved in sterile water and saline, respectively, immediately prior to each 
experiment, and fresh cation-adjusted Mueller–Hinton broth (Ca2+ at 25.0 mg/L and Mg2+ at 
12.5 mg/L; Difco, Detroit, MI) prepared prior to each experiment was used for all in vitro 
experiments and for susceptibility testing. Static time–kill experiments were conducted to 
characterise the pharmacodynamics of PMB and tigecycline alone and in combination [6]. A 
4 × 4 concentration array of PMB (2, 8, 16 and 20 mg/L) and tigecycline (0.15, 0.90, 2 and 4 
mg/L) [7] against low inocula (106 CFU/mL) and high inocula (108 CFU/mL) was 
evaluated. Serial cultures were obtained over 48 h. Bacterial counts were determined based 
on quantitative cultures on Mueller–Hinton agar plates after 24 h of incubation at 37 °C.
The pharmacodynamic analysis was performed by evaluating microbiological responses to 
monotherapy and combination therapy by determining the log10 change, calculating the 
change in bacterial density at 4, 8, 24 and 48 h from baseline (0 h) to characterise early and 
late pharmacodynamic activities for monotherapy and combination therapy. Bactericidal 
activity was defined as a ≥3 log10 CFU/mL reduction. Regimens were categorised based on 
the reduction in the initial bacterial inoculum, where activity was defined as at least 1 log10 
CFU/mL reduction compared with the initial inoculum. Additivity and synergy were defined 
as 1.0 to <2 log10 CFU/mL and ≥2 log10 CFU/mL reduction by the PMB + tigecycline 
combination compared with the most active single agent in the combination, respectively 
[8].
3. Results
The results of time–kill studies for PMB and tigecycline alone and in combination against 
low and high inocula of both isolates are summarised in Figs 1 and 2. At the lower inoculum 
of 106 CFU/mL, PMB monotherapy achieved early bactericidal activity, and sustained 
activity was seen with the higher PMB concentrations of 16 mg/L and 20 mg/L against the 
PBS isolate [Fig. 1(A1)]. Tigecycline monotherapy at 0.15 mg/L [Fig. 1(A2)] and 0.90 mg/L 
[Fig. 1(A3)] performed no different from the growth control against the PBS isolate. 
Monotherapy at the higher tigecycline concentrations of 2 mg/L [Fig. 1(A4)] and 4 mg/L 
[Fig. 1(A5)] resulted in >1 log10 reduction by 8 h followed by re-growth. All tigecycline 
concentrations in combination with the clinically achievable PMB concentration of 2 mg/L 
resulted in early bactericidal activity followed by re-growth beyond 8 h, whereas in 
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combination with the higher PMB concentrations of 16 mg/L and 20 mg/L, it resulted in 
sustained bactericidal activity against the PBS isolate [Fig. 1(A2–A5); Table 1].
Against the lower inoculum of the PBR isolate, monotherapy with tigecycline and PMB was 
no different from the growth control [Fig. 1(B1–B5); Table 1]. The clinically achievable 
tigecycline concentration of 0.15 mg/L in combination with all PMB concentrations did not 
result in appreciable sustained activity [Fig. 1(B2); Table 1]. Comparatively, the higher 
tigecycline concentration of 0.90 mg/L in combination with PMB concentrations of 2 mg/L 
and 8 mg/L resulted in early >1 log10 reduction of the PBR inoculum up to 8 h, whilst 
combination with higher PMB concentrations of 16 mg/L and 20 mg/L resulted in sustained 
bactericidal activity up to 24 h [Fig. 1(B3); Table 1]. Tigecycline 2 mg/L and 4 mg/L in 
combination with PMB 8, 16 and 20 mg/L demonstrated synergy and resulted in sustained 
bactericidal activity up to 48 h, whilst combination with PMB 2 mg/L showed a lack of 
activity beyond 8 h against the PBR isolate [Fig. 1(B4 and B5); Table 1].
Monotherapy with either PMB or tigecycline against the higher inoculum of the PBS isolate 
demonstrated a lack of activity at 48 h with the exception of tigecycline 4 mg/L resulting in 
a 1.30 log10 reduction [Fig. 2(A1–A5); Table 1]. Similarly, no activity was seen with 
clinically achievable concentrations of tigecycline 0.15 mg/L and 0.90 mg/L in combination 
with PMB 2 mg/L. Tigecycline 0.15 mg/L in combination with PMB 20 mg/L and 
tigecycline 0.90 mg/L in combination with PMB 16 mg/L and 20 mg/L resulted in >3 log10 
reduction beyond 24 h [Fig. 2(A2 and A3); Table 1]. Tigecycline 2 mg/L and 4 mg/L in 
combination with PMB 2 mg/L resulted in >2 log10 reduction by 8 h, whereas combinations 
with PMB concentrations >2 mg/L were synergistic and resulted in sustained bactericidal 
activity against the PBS isolate beyond 8 h [Fig. 2(A4 and A5); Table 1].
Similar to the high inoculum of the PBS isolate, against the high inoculum of the PBR isolate 
monotherapy with either PMB or tigecycline demonstrated attenuated killing [Fig. 2(B1–
B5)]. Tigecycline 0.15 mg/L in combination with PMB was similar to monotherapy with 
respect to its killing activity [Fig. 2(B2); Table 1]. Tigecycline 0.90 mg/L in combination 
with PMB concentrations of 8, 16 and 20 mg/L resulted in an early reduction of >1 log10 by 
8 h that was followed by re-growth [Fig. 2(B3); Table 1]. Tigecycline 2 mg/L and 4 mg/L in 
combination with PMB 2 mg/L resulted in >1 log10 reduction of the initial high inoculum of 
the PBR isolate. These higher tigecycline concentrations in combination with PMB 8, 16 and 
20 mg/L were synergistic, resulting in sustained killing activity of the PBR isolate [Fig. 2(B4 
and B5); Table 1].
4. Discussion
Treatment of infections caused by A. baumannii is a growing clinical problem due to its 
intrinsic ability to acquire antibiotic resistance genes via multiple mechanisms and to 
develop resistance [9]. A number of previous studies have explored polymyxin and 
tigecycline combinations, with outcomes ranging from indifference to synergy [10–12]. In 
the current study, at the lower inoculum, a clinically achievable PMB concentration of 2 
mg/L combined with tigecycline 0.90 mg/L resulted in a 6.38 log10 reduction by 8 h, which 
was synergistic by 24 h against the PBS reference strain, followed by re-growth by 48 h. 
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These observations from the current study are consistent with the findings of Yilmaz et al 
[12] who showed that colistin in combination with tigecycline against A. baumannii isolates 
in a time–kill study resulted in early bactericidal activity by 4 h at concentrations of 4× MIC 
that was sustained for 24 h (colistin MIC, 0.25 mg/L; tigecycline MIC, 1.0 mg/L). The 
authors attributed the attenuated in vivo activity to the lack of knowledge about colistin 
pharmacokinetics precluding accurate determination of the optimum colistin dose in rats. 
Furthermore, the 48 h endpoint does not accurately reflect the true clinical picture in 
patients, in which there is a time lag before observable colistin plasma concentrations are 
achieved. A loading dose of colistin would therefore be beneficial to reduce this time lag in 
practice [13,14].
Hagihara et al observed that PMB was responsible for the majority of the antibacterial effect 
against four carbapenem-resistant A. baumannii isolates tested with PMB (MIC of 1 mg/L) 
and tigecycline (MICs ranging from 1 mg/L to 4 mg/L) [10]. Similar to our observations, 
there was a lack of appreciable activity with tigecycline monotherapy. As the area under the 
concentration–time curve of the free (unbound) drug (fAUC)/MIC ratio was the 
pharmacodynamic parameter of interest, tigecycline dosing regimens of ≥200 mg daily were 
required to achieve fAUC/MIC exposures of 2.17 and 8.78 for 1 and 2 log10 reductions in 
bacterial density, respectively. This tigecycline regimen of 200 mg resulted in a mean change 
in bacterial density of 0.80 ± 0.59 log10 CFU/mL at 24 h with an initial inoculum of 106 
CFU/mL. Simulated PMB monotherapy regimens of 1 mg/kg resulted in a mean change of 
−2.05 ± 0.68 log10 CFU/mL at 24 h with an initial inoculum of 106 CFU/mL. Combination 
therapy resulted in bactericidal activity with a reduction of 3.31 ± 0.71 log10 CFU/mL at 24 
h [10].
In vitro models of infection may be useful for identifying potential synergy between 
different tigecycline and polymyxin concentrations, evaluated against the more susceptible 
isolates, at certain time points during the time course of the experiment. However, studies 
conducted over 24 h were unable to ascertain whether the suppression of resistant bacterial 
subpopulations is sustained beyond 24 h at the studied concentrations. In an attempt to 
optimise tigecycline regimens, Xie et al concluded that the clinical effectiveness of current 
standard tigecycline dosing was less than adequate given the continued resistance and 
reduced AUC in vivo against MDR A. baumannii strains with enhanced MICs [15]. 
Therefore, bacterial density and duration of in vitro studies are important to consider when 
evaluating these polymyxin combinations. Recently, tigecycline in combination with colistin 
for the treatment of bacteraemia due to extensively drug-resistant A. baumannii was shown 
to be associated with decreased bacteriological clearance and increased 14-day mortality 
[16]. In this study (55 patients met the inclusion criteria: 29 received colistin in combination 
with tigecycline and 26 received colistin with a carbapenem), the crude 14-day mortality 
was markedly higher in the colistin–tigecycline group compared with the colistin–
carbapenem group (35% vs. 15%; P = 0.105); breakthrough bacteraemia due to A. 
baumannii was also 18% higher in the colistin + tigecycline group. Furthermore, over the 
duration of the study, 10 (71.4%) of the 14 non-surviving patients received colistin–
tigecycline (P = 0.010). The findings from the abovementioned study are similar to the 
findings of the current study indicating that pre-existing reduced tigecycline susceptibilities 
among carbapenem-resistant A. baumannii isolates and pretreatment tigecycline MIC ≥ 2 
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mg/L may be indicative of poor clinical outcomes even when tigecycline is used in 
combination. This could be attributed to the fact that tigecycline is bacteriostatic and is 
widely distributed in the tissues resulting in low serum concentrations.
Taken together with the current data, it is prudent to conclude that administering either 
tigecycline or PMB as monotherapy or even in a traditional manner in combination against 
A. baumannii strains with reduced tigecycline susceptibilities is not recommended, 
particularly in infections with heterogeneous susceptibility and markedly higher bacterial 
density [2]. However, against A. baumannii strains susceptible to tigecycline with MICs ≤ 2 
mg/L, at infection sites where tigecycline can achieve adequately high concentrations, these 
data may hold particular relevance in the selection of treatment. As it relates to the clinical 
use of tigecycline, tigecycline-based therapy has been compared with colistin-based therapy 
for the treatment of MDR A. baumannii infections [16,17]. Colistin-based therapy has been 
shown to be associated with lower in-hospital mortality and higher microbial eradication 
rates. The resulting suboptimal drug concentrations in serum and epithelial lining fluids with 
tigecycline makes physicians favour the use of high-dose tigecycline combination regimens 
for the treatment of MDR infections [18].
5. Conclusions
These in vitro results are indicative that against highly resistant strains with high inoculum, 
tigecycline in combination with PMB results only in a transitory effect with clinically 
achievable PMB and tigecycline concentrations. Furthermore, outcomes for patients with 
infections due to MDR A. baumannii are poor and are associated with high mortality, 
highlighting the importance of exploring non-traditional dosing and combinatorial 
approaches. Hence, the results presented here are indicative of the urgent need for newer 
antimicrobial agents with novel targets to help address the lack of viable treatment options 
against such hard-to-treat MDR pathogens.
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Fig. 1. 
Time–kill experiments with polymyxin B (PB) monotherapy (A1, B1) and tigecycline (TIG) 
0.15 mg/L (A2, B2), TIG 0.90 mg/L (A3, B3), TIG 2 mg/L (A4, B4) and TIG 4 mg/L (A5, 
B5) alone and in combination against an initial low inoculum of 106 CFU/mL of 
Acinetobacter baumannii reference strain ATCC 19606 (A) and clinical isolate FADDI 
AB115 (B).
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Fig. 2. 
Time–kill experiments with polymyxin B (PB) monotherapy (A1, B1) and tigecycline (TIG) 
0.15 mg/L (A2, B2), TIG 0.90 mg/L (A3, B3), TIG 2 mg/L (A4, B4) and TIG 4 mg/L (A5, 
B5) alone and in combination against an initial high inoculum of 108 CFU/mL of 
Acinetobacter baumannii reference strain ATCC 19606 (A) and clinical isolate FADDI 
AB115 (B).
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Table 1
Changes in bacterial density (log10 CFU/mL) at 4, 8, 24 and 48 h compared with the initial inoculum (0 h) for 
polymyxin B (PMB) and tigecycline (TIG) combination therapy against the initial inocula of 106 CFU/mL and 
108 CFU/mL of heteroresistant Acinetobacter baumannii reference strain ATCC 19606 and clinical isolate 
FADDI AB115.
Regimens were categorised based on the reduction in the initial bacterial inoculum, where grey shading highlights activity (at least 1 log10 
CFU/mL reduction), orange shading indicates additivity (at least 1.0 to <2 log10 CFU/mL reduction) and green shading indicates synergy (at least 
≥2 log10 CFU/mL reduction) by the combination of PMB and TIG compared with the most active single agent in the combination. Bold type 
indicates bactericidal activity (≥3 log10 CFU/mL reduction).
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